Products

The Syneture division of United States Surgical, Norwalk, CT, has received Food and Drug Administration (FDA) approval to market INDERMIL Tissue Adhesive with the additional claim that it acts as a barrier to microbial penetration as long as the adhesive film remains intact. Indermil is indicated for the closure of topical skin incisions and lacerations, setting a thin film over wound edges to seal out common forms of bacteria that may cause infection.

INDERMIL Tissue Adhesive was developed and is manufactured by Henkel Loctite Ltd (a subsidiary of Henkel Corporation) in Dublin, Ireland, and is distributed by Syneture.

In addition, Syneture has received FDA approval to market the Kendall Monoject Bluntip I.V. Access Cannula as an INDERMIL Tissue Adhesive accessory product. The cannula may be affixed to the INDERMIL ampule tip to provide greater visibility when applying the tissue adhesive by positioning the clinician's hand, which is lightly squeezing the ampule above the wound, making the wound easier to see. The cannula also requires less force to dispense 10 drops of the product through its smaller opening.

Companies

PDI, Inc, Upper Saddle River, NJ, has notified Xylos Corporation, Langhorne, PA, of its intent to terminate its sales, marketing, and distribution agreement to promote Xylos'XCELL Wound Care Products. The termination will take effect May 16, 2004, which follows the 135-day notice required by the agreement. PDI is a health care sales and marketing company that provides strategic financial alternatives for biopharmaceutical and medical device and diagnostics manufacturers.